Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19897. Online ahead of print.
ABSTRACT
BACKGROUND: Dupilumab was equally effective among all racial subgroups in clinical trials, but a direct comparison in daily practice is lacking.
OBJECTIVE: To investigate effectiveness of dupilumab in atopic dermatitis (AD) patients in the Netherlands versus Japan up to 80 weeks of treatment.
METHODS: A longitudinal comparative cohort study was conducted in AD patients who were treated with dupilumab in daily practice. We used linear mixed-effects models to determine changes in time.
RESULTS: We found statistically significant differences in sex, disease onset, BMI and therapeutic history between Dutch (n=208) and Japanese (n=153) patients. The baseline Eczema Area and Severity Index (EASI) score was higher in Japanese patients (23.8 v.s. 14.8), while baseline Patient-Reported Outcome Measures (PROMs) were higher in Dutch patients. EASI scores decreased quickly to a level indicating “mild disease” (EASI < 7), and remained low in both countries. However, PROMs showed different trajectories with better scores in Japan.
CONCLUSION: Dupilumab showed significant, comparable, and sustained improvement of EASI scores in Japanese and Dutch patients. However, we found striking differences in the effect on PROMs between the countries, with a better outcome in Japanese patients.
PMID:33657668 | DOI:10.1111/bjd.19897
